BT200

DRUG3 trials

Sponsors

Band Therapeutics, Medical University of Vienna

Conditions

Cerebrovascular StrokeHemophilia AIntracranial ArteriosclerosisLarge-Artery Atherosclerosis (Embolus/Thrombosis)Von Willebrand Disease (VWD), Type 2Von Willebrand Diseases

Phase 1

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

CompletedNCT04103034

Band TherapeuticsCerebrovascular Stroke, Intracranial Arteriosclerosis, Large-Artery Atherosclerosis (Embolus/Thrombosis)

Start: 2019-10-07End: 2020-09-14Updated: 2024-03-18

Phase 2

BT200 in Hereditary Bleeding Disorders

CompletedNCT04677803

Medical University of ViennaHemophilia A, Von Willebrand Diseases

Start: 2020-12-14End: 2021-09-10Updated: 2021-11-11

Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease

RecruitingNCT07273721

Medical University of ViennaVon Willebrand Disease (VWD), Type 2

Start: 2025-08-14End: 2026-07-31Target: 6Updated: 2025-12-09

Related Papers

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Blood2022-09-1522 citations

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease

Blood Advances2022-06-3026 citations